Results 61 to 70 of about 4,843 (156)

Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis.

PLoS ONE, 2023
BackgroundAtherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system.
Tasnim F Imran, Ali A Khan, Phinnara Has, Alexis Jacobson, Stephanie Bogin, Mahnoor Khalid, Asim Khan, Samuel Kim, Sebhat Erqou, Gaurav Choudhary, Karen Aspry, Wen-Chih Wu   +11 more
doaj   +1 more source

The wind of change – PCSK9 inhibitors in hypolipidemic treatment. The Polish perspective

Journal of Education, Health and Sport, 2023
Introduction and aim. Cardiovascular diseases are the main cause of mortality in the world. One of the alterable risk factors of ischaemic heart disease is dyslipidemia.
Natalia Ilnicka, Patrycja Zuziak, Maria Sadlik, Daria Matyja, Leila Abod   +4 more
doaj   +1 more source

DrugUtilisation: An R Package to Support Drug Utilisation Research Using the OMOP Common Data Model

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 7, July 2026.
ABSTRACT Purpose To develop and describe DrugUtilisation, an open‐source R package that facilitates drug utilisation studies using data mapped to the OMOP Common Data Model (CDM). Methods Core functionalities include creating drug user cohorts, identifying and summarising indications, describing the duration and dose of medication/s and assessing ...
Yuchen Guo, Edward Burn, Annika M. Jödicke, Núria Mercadé‐Besora, Kim Lopez‐Güell, Xihang Chen, Mike Du, Xintong Li, Raivo Kolde, Marek Oja, Mees Mosseveld, Katia Verhamme, Julieta Politi, Antonella Delmestri, Wai Yi Man, Peter Rijnbeek, Daniel Prieto‐Alhambra, Martí Català   +17 more
wiley   +1 more source

A 32‐Year‐Old Man With an Cardiomyopathy

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Scleredema is a sclerosing dermatosis of unknown etiology, characterized by non‐punctate, weakly infiltrated skin thickening and swelling, which can lead to the development of cardiomyopathy. Scleredema‐associated cardiomyopathy is at present poorly understood.
Yuting Zou, Shan Li, Tong Chen, Yi Li
wiley   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1547-1554, June 2026.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon, Chen Gurevitz, Tzippy Shochat, Shiri Kushnir, Guy Witberg, Amos Levi, Dan Gilon, Ran Kornowski, Paaladinesh Thavendiranathan, Husam Abdel Qadir, Zaza Iakobishvili   +10 more
wiley   +1 more source

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

, 2019
Background: After acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A reduction in mean LDL cholesterol to 1·4–1·8 mmol/L with ezetimibe or statins reduces cardiovascular events in patients with an acute ...
Diaz, R, Hanotin, C, Loizeau, V, Coverdale, S, Colhoun, HM, Bittner, VA, Goodman, SG, Bhatt, DL, Baccara-Dinet, M, Harrington, RA, Budaj, AJ, Jukema, JW, Ray, KK, et al., Szarek, M   +14 more
core   +1 more source

Dynamics of lipid metabolism parameters following the change of targeted therapy for hypercholesterolemia after acute coronary syndrome

Терапевтический архив
Aim. To evaluate lipid metabolism dynamics by switch from inclisiran to alirocumab in the setting of lipid-lowering therapy (LLT) after acute coronary syndrome (ACS). Materials and methods.
Aleksei A. Nekrasov, Elena S. Timoshchenko, Svetlana G. Erofeeva, Elena S. Kuzyakina, Tatiana A. Nekrasova   +4 more
doaj   +1 more source

PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo

JACC: Basic to Translational Science, 2016
To elucidate how the proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor alirocumab modulates lipoprotein(a) [Lp(a)] plasma levels, the authors performed a series of Lp(a) uptake studies in primary human hepatocytes and dermal fibroblasts and
Elise F. Villard, PhD, Aurélie Thedrez, PhD, Jorg Blankenstein, PhD, Mikaël Croyal, BSc, Thi-Thu-Trang Tran, PhD, Bruno Poirier, PhD, Jean-Christophe Le Bail, PhD, Stéphane Illiano, PhD, Estelle Nobécourt, MD, PhD, Michel Krempf, MD, PhD, Dirk J. Blom, MD, PhD, A. David Marais, MD, Philip Janiak, PhD, Anthony J. Muslin, MD, PhD, Etienne Guillot, PhD, Gilles Lambert, PhD   +15 more
doaj   +1 more source

Impact of CYP2C19 Genotype Variants on PCSK9 Inhibitor Efficacy in Lipid‐Lowering Among Patients With Symptomatic Intracranial Atherosclerotic Stenosis

Lipids, Volume 61, Issue 3, Page 319-329, May 2026.
ABSTRACT Ischemic stroke is frequently associated with symptomatic intracranial atherosclerotic stenosis (sICAS), is a leading cause of global disability and mortality. Current guidelines recommend dual antiplatelet and intensive statin therapies. Proprotein convertase subtilisin 9/kexin type 9 (PCSK9) inhibitors have emerged as a potent lipid‐lowering
Chao Zhao, Nuan Wang, Di Shi, Hao Zhou, Dan Chen, Guofang Chen   +5 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source